Assessment of the anticonvulsant activity of pyrazolo[1,5-a][1,3,5]triazines obtained by synthesis by Insuasty, Henry et al.
22
Rev. Colomb. Cienc. Quím. Farm., Vol. 43 (1), 22-38, 2014                                             www.farmacia.unal.edu.co
Artículo de investigación científica
Assessment of the anticonvulsant activity of 
pyrazolo[1,5-a][1,3,5]triazines obtained by 
synthesis
 Henry Insuasty1, Édison Castro1,2, Juan C. Escobar3, Vanessa Murillo3, Jeanette Rodríguez3, Luis 
E. Cuca4, Martín Estrada3, Braulio Insuasty2, Mario F. Guerrero3* 
1  Department of Chemistry, Universidad de Nariño, Pasto, Colombia, A. A. 1175. 
2  Department of Chemistry, Universidad del Valle, Cali, Colombia.
3  Department of Pharmacy, Faculty of Sciences, Universidad Nacional de Colombia, Bogotá. * A. 
A.: 14490. Email: mfguerrerop@unal.edu.co.
4  Department of Chemistry, Faculty of Sciences, Universidad Nacional de Colombia.
Recibido para evaluación: 19 de enero de 2014.
Aceptado para publicación: 15 de mayo de 2014.
Summary
Giving that the pyrazolo[1,5-a][1,3,5]triazine system is a potential source of phar-
macological agents for treatment of central nervous system disorders this work was 
aimed to asses anticonvulsant and acute neurotoxic effects of six molecules obtained 
by synthesis, using experimental models in mice. A series of six pyrazolo[1,5-a]
[1,3,5]triazines (EAC-21, EAC-31, EAC-33, MH4a, MH4b1 and MH4c) 
obtained by one-step reaction from S,S-diethyl aroyl-/hetaroylimidodithiocarbon-
ates and 5-aminopyrazoles were screened in vivo (300 mg/kg, v.o.) for their anticon-
vulsant activity in the maximal electroshock (MES) test in ICR mice and for acute 
toxicity in the rota-rod and wiring test. The structures of the obtained compounds 
were unambiguously established by IR, 1H and 13C-NMR spectroscopic techniques, 
COSY 1H-1H, hsqc and hmbc experiments, mass spectrometry and elemental 
analyses. Results shown that only MH4b1 showed protection against MES (p < 
0.05) and was devoid of gross neurotoxicity signs. Therefore, MH4b1 was chosen 
for additional anticonvulsant screening against MES, pentylenetetrazole, picro-
toxin, strychnine and 6 Hz psychomotor seizure model, in a dose dependent manner 
(50, 150, 300 mg/kg, v.o.). MH4b1 also protected against 6 Hz seizure test (> 150 
mg/kg, v.o.). These data suggest that MH4b1 could be a source for anticonvulsant 
pyrazolo[1,5-a][1,3,5]triazine analogs potentially useful against tonic clonic and 
refractory seizures.
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Resumen
Evaluación de la actividad anticonvulsivante de pirazolo[1,5-a]
[1,3,5]triazinas obtenidas por síntesis
Dado el interés que el sistema pirazolo[1,5-a][1,3,5]triazínico tiene como fuente 
potencial para la obtención de agentes farmacológicos para el tratamiento de tras-
tornos del sistema nervioso central, en este trabajo se efectuó el cribado anticonvul-
sivante y el efecto neurotóxico agudo de seis moléculas derivadas de este sistema, 
en ratones ICR. La serie de compuestos denominados EAC-21, EAC-31, EAC-33, 
MH4a, MH4b1 y MH4c, obtenidas por la reacción de S,S-dietil aroil-/hetaroili-
midoditiocarbonatos y 5-aminopirazoles se evaluó in vivo (300 mg/kg, v.o.) en la 
prueba de convulsiones inducidas por electrochoque y en las pruebas de actividad 
neurotóxica aguda del eje rodante y del alambre. La estructura de estos compuestos 
se estableció con las técnicas espectroscópicas de IR, RMN-1H, RMN-13C, los 
experimentos COSY 1H-1H, HSQC Y HMBC, espectrometría de masas y análisis 
elemental. Los resultados mostraron que el compuesto MH4b1 confirió protección 
frente a las convulsiones inducidas por electrochoque (p < 0,05) sin producir signos 
de neurotoxicidad aguda. Por consiguiente, MH4b1 se escogió para las siguientes 
pruebas de actividad anticonvulsivante, dosis – respuesta (50, 150, 300 mg/kg, v.o.): 
electrochoque, pentilenetetrazol, picrotoxin, estricnina y el modelo de convulsión 
psicomotora de 6 Hz. MH4b1 mostró efectos protectores en función de la dosis 
frente a las pruebas de convulsión por electrochoque (> 150 mg/kg) y convulsión de 
6 Hz (300 mg/kg, v.o.). Estos resultados sugieren que MH4b1 podría constituirse en 
fuente anticonvulsivante del sistema pirazolo[1,5-a][1,3,5]triazínico eventualmente 
útil para el tratamiento de las crisis tónicas clónicas generalizadas y las crisis refractarias. 
Palabras clave: pirazolotriazinas, anticonvulsivantes, evaluación preclínica de medi-
camentos, electrochoque, relación estructura - actividad.
Introduction
The pyrazolo[1,5-a][1,3,5]triazine system has become of great interest in experimen-
tal pharmacology in view of its potential utility against a wide variety of biological 
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disorders like chronic obstructive pulmonary disease, psoriasis [1, 2], cancer [3, 4, 5], 
bacteria, fungal and viral infections [6, 7, 8, 9]. Disorders of the central nervous system 
also are a potential target of pyrazolo[1,5-a][1,3,5]triazine system, including major 
depression [10, 11] and cognitive disfunction [12], among others.
Epilepsy is the most prevalent neurologic disorder and its morbidity and mortality is 
high in industrialized and developing countries [13, 14, 15]. Available drug therapy 
despite the improvements introduced in the last decades, is facing an important side 
effect profile and insufficient effectiveness in a significant number of patients [16]. 
Refractactory epilepsy is a challenge key factor in searching for effective anticonvul-
sant agents [17]. New therapeutic alternatives from natural or synthetic sources may 
contribute to the treatment of this disease [18].
Insuasty et al. developed an efficient method for the preparation of pyrazolo[1,5-a]
[1,3,5]triazines by the interaction of S,S-diethyl aroyliminodithiocarbonates with 
5-amino-3-methylpyrazole to obtain novel 4-aryl-2-ethylthio-7-methylpyrazolo[1,5-a]
[1,3,5]triazines [19, 20, 21]. In view of potential CNS depressant activities of the 
pyrazolo[1,5-a]-[1,3,5]-triazine system herein is reported the anticonvulsant profile of 
the following compounds: EAC-21, EAC-31, EAC-33, MH4a, MH4b1 and MH4c, 
exposed to electrical and chemical experimental seizures induced in ICR albino mice.
Methodology
Chemistry 
The general synthesis of the desired pyrazolotriazines 3a-c (3a = MH4a, 3b = MH4b1 
and 3c = MH4c) and 6a-c (6a = EAC-33, 6b = EAC-21 and 6c = EAC-31) is sum-
marized in scheme 1. Tested pyrazolotriazines are represented in the Figure 1.
General procedure for the synthesis of pyrazolo[1,5-a][1,3,5]triazines 3a-c (3a = 
MH4a, 3b = MH4b1 and 3c = MH4c).
Pyrazolo[1,5-a][1,3,5]triazines 3a-c were synthetized by heating under reflux a solu-
tion of S,S-diethyl aroylimidodithiocarbonates 1a-c (0.003 mol) and 5-amino-3-
methylpyrazole 2 (0.003 mol) in dimethylformamide (2 mL), according to the method 
described by Insuasty et al. (2006). The solid product was precipitated by the addi-
tion of cold water to the reaction mixture; the precipitate was collected by filtration 
and purified by column chromatography on silica gel using a mixture of hexanes/ethyl 
acetate (4:1) as eluent. Melting point values as well as 1H and 13C nuclear magnetic 
resonance spectra were consistent with the proposed structures.
Anticonvulsant activity of pyrazolo[1,5-a][1,3,5]triazines
25
Scheme 1. Synthesis of target pyrazolo[1,5-a][1,3,5]triazines 3a-c and 6a-c.
Figure 1. Tested pyrazolo[1,5-a][1,3,5]triazines.
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Data for 2-ethylthio-7-methyl-4-phenylpyrazolo[1,5-a][1,3,5]triazine (3a = MH4a). 
Yellow solid, mp 94 °C (90 %). 1H NMR (400 MHz, DMSO): δ 1.36 (t, 3H, CH3), 
3.16 (c, 2H, CH2), 6.41 (s, 1H, 8-H), 7.62 (t, 2H, Hm), 7.70 (t, 1H, Hp), 8.57 (d, 2H, 
Ho). 13C NMR (DMSO): δ 14.3 (CH3), 14.6 (7-CH3), 24.8 (CH2), 94.2 (C-8), 128.4 
(Cm), 129.6 (Ci), 130.9 (Co), 133.1 (Cp), 152.0 (C-4), 150.8 (C-8a), 157.4 (C-7), 
165.0 (C-2). MS (70 eV) m/z (%): 270 (M+, 100), 255 (28), 139 (20), 70 (18), 51 
(19), 39 (16). Anal. Calcd. for C14H14N4S: C, 62.20; H, 5.22; N, 20.72. Found: C, 
62.16; H, 5.24; N, 20.67. 
Data for 2-ethylthio-7-methyl-4-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triazine (3b = 
MH4b1). Green solid, mp 112 °C (63 %). 1H NMR (400 MHz, DMSO): δ 1.40 (t, 3H, 
CH3), 2.45 (s, 3H, 7-CH3), 3.19 (c, 2H, CH2), 6.33 (s, 1H, 8-H), 7.42 (d, 2H, Hm), 
8.58 (d, 2H, Ho). 13C NMR (DMSO):  13.6 (CH3), 13.8 (7-CH3), 24.3 (CH2), 93.3 
(C-8), 126.5 (Ci), 128.3 (Cm), 130.4 (Co), 143.1 (Cp), 151.3 (C-4), 150.5 (C-8a), 
156.8 (C-7), 164.6 (C-2). MS (70 eV) m/z (%): 284 (M+, 100), 269 (22), 251 (57), 
139 (27), 118 (24), 70 (15), 39 (15). Anal. Calcd. for C15H16N4S: C, 63.35; H, 5.67; 
N, 19.70. Found: C, 63.38; H, 5.63; N, 19.69. 
Data for 2-ethylthio-4-(4-chlorophenyl)-7-methylpyrazolo[1,5-a][1,3,5]triazine (3c = 
MH4c). Green solid, mp 104 °C (93 %). 1H NMR (400 MHz, DMSO): δ 1.35 (t, 3H, 
CH3), 2.40 (s, 3H, 7-CH3), 3.13 (c, 2H, CH2), 6.36 (s, 1H, 8-H), 7.66 (d, 2H, Hm), 
8.80 (d, 2H, Ho). 13C NMR (DMSO):  14.2 (CH3), 14.5 (7-CH3), 24.8 (CH2), 94.1 
(C-8), 128.3 (Cm), 128.5 (Ci), 132.7 (Co), 138.0 (Cp), 151.3 (C-4), 150.7 (C-8a), 
157.4 (C-7), 164.8 (C-2). MS (70 eV) m/z (%): 304/306 (M+, 100/42), 289 (23), 
273 (20), 271 (52), 139 (45), 138 (32), 137 (18), 110 (20), 81 (20), 70 (17), 51 (17), 
39 (18). Anal. Calcd. for C14H13N4SCl: C, 55.17; H, 4.30; N, 18.38. Found: C, 55.21; 
H, 4.28; N, 18.35. 
General procedure for the synthesis of pyrazolo[1,5-a][1,3,5]triazines 6a-c (6a = 
EAC-33, 6b = EAC-21 and 6c = EAC-31) [21].
A mixture of the appropriate S,S-diethyl hetaroylimidodithiocarbonate 4a,b (0.015 
mol) and the corresponding 5-amino-3-hetaryl-1H-pyrazole 5a,b (0.015 mol) was 
subjected to microwave irradiation in absence of solvent (maximum power 300W dur-
ing 10-20 min at a temperature in the range of 160 to 180 oC), using a focused micro-
wave reactor (CEM discover). When finished (TLC control), the crude product was 
dissolved in chloroform (3.0 mL) and purified by column chromatography on silica 
gel, using a mixture of hexanes/ethyl acetate (9:1) as eluent.
Note: For describing the spectroscopic data of compounds 6a-c, the heteroaromatic 
rings (Het1 and Het2) have been denoted by the letters A and B, respectively.
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Data for 2-ethylthio-4,7-di(2-furyl)pyrazolo[1,5-a][1,3,5]triazine (6a = EAC-33). 
Yellow solid, mp 148-149 oC (95 %). 1H NMR (CDCl3): δ 1.48 (t, 3H, CH3), 3.26 (q, 
2H, CH2), 6.58 (dd, 1H, HB-4), 6.65 (s, 1H, H-8), 6.77 (dd, 1H, HA-4), 7.04 (d, 1H, 
HB-5), 7.61 (d, J = 1.8 Hz, 1H, HB-3), 7.86 (d, 1H, HA-5), 8.52 (d, 1H, HA-3). 
13C 
NMR (CDCl3): δ 14.2 (CH3), 25.6 (CH2), 91.2 (C-8), 109.7 (CB-3), 111.9 (CB-5), 
113.2 (CB-4), 125.1 (CA-4), 142.9 (CA-2), 143.3 (CB-2), 143.9 (CA-5), 147.9 (C-8a), 
148.2 (CA-3), 150.3 (C-7), 150.9 (C-4), 166.9 (C-2). MS (70 eV) m/z (%): 312 (100, 
M+), 297 (19), 279 (41), 191 (51), 159 (43), 133 (28), 105 (30), 90 (55), 29 (63). 
Anal. Calcd. for C15H12N4O2S: C, 57.68; H, 3.87; N, 17.94. Found: C, 57.71; H, 3.85; 
N, 17.92. 
Data for 2-ethylthio-4,7-di(2-thienyl)pyrazolo[1,5-a][1,3,5]triazine (6b = EAC-21). 
Yellow solid, mp 163-164 oC (90 %). 1H NMR (CDCl3): δ 1.50 (t, 3H, CH3), 3.26 
(q, 2H, CH2), 6.60 (s, 1H, H-8), 7.16 (dd, 1H, HB-4), 7.31 (dd, 1H, HA-4), 7.45 (dd, 
1H, HB-5), 7.63 (dd, 1H, HB-3), 7.84 (dd, 1H, HA-5), 8.94 (dd, 1H, HA-3). 
13C NMR 
(CDCl3): δ 14.4 (CH3), 25.7 (CH2), 90.9 (C-8), 127.1 (CB-3), 127.4 (CB-5), 127.9 
(CB-4), 128.5 (CA-4), 132.3 (CA-2), 135.5 (CB-2), 135.9 (CA-5), 137.2 (CA-3), 147.4 
(C-8a), 151.4 (C-7), 153.4 (C-4), 166.5 (C-2). MS (70 eV) m/z (%): 344 (41, M+), 
311 (16), 270 (16), 207 (18), 178 (35), 134 (24), 110 (48), 70 (61), 45 (54), 29 (100). 
Anal. Calcd. for C15H12N4S3: C, 52.30; H, 3.51; N, 16.26. Found: C, 52.31; H, 3.52; 
N, 16.22.
Data for 2-ethylthio-7-(2-furyl)-4-(2-thienyl)pyrazolo[1,5-a][1,3,5] triazine (6c = 
EAC-31). Yellow solid, mp 108-109 oC (91%). 1H NMR (CDCl3): δ 1.50 (t, 3H, 
CH3), 3.27 (q, 2H, CH2), 6.60 (dd, 1H, HB-4), 6.64 (s, 1H, H-8), 7.07 (d, 1H, HB-5), 
7.32 (t, 1H, HA-4), 7.62 (d, 1H, HB-3), 7.84 (d, 1H, HA-5), 8.97 (d, 1H, HA-3). 
13C 
NMR (CDCl3): δ 14.4 (CH3), 25.7 (CH2), 90.9 (C-8), 109.8 (CB-3), 111.9 (CB-5), 
128.5 (CB-4), 132.4 (CA-2), 135.8 (CA-4), 137.3 (CA-5), 143.9 (CA-3), 147.6 (CB-2), 
147.9 (C-8a), 150.3 (C-7), 151.2 (C-4), 166.5 (C-2). MS (70 eV) m/z (%): 328 
(100, M+), 313 (22), 268 (38), 219 (35), 191 (93), 94 (55), 27 (29). Anal. Calcd. for 
C15H12N4OS2: C, 54.86; H, 3.68; N, 17.06. Found: C, 54.84; H, 3.65; N, 17.03.
Animals
Male 9-11 week-old ICR albino mice, weighing between 20 and 30g obtained from the 
Department of Pharmacy, National University of Colombia were used in this study. 
They were held in conditions of controlled temperature and humidity, photoperiod 
of 12 hours light/darkness and free access to food and water, except on the test day. 
The animals were subjected to a fasting period of no more than six hours during the 
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test day in order to not affect the convulsive threshold [22]. 7-8 animals per each dose 
were used. According to guidelines about anticonvulsant screening and amount of 
synthesized compounds, an initial 300 mg/kg, p.o. dose was chosen, administered by 
intragastric cannulation [23]. The maximal electroshock seizure model (MES) in mice 
was used as first screening assay for comparison to all compounds. Rota rod and wiring 
tests were applied immediately before MES test in order to assess the acute neurotoxic 
effects. The compound that attained greater anticonvulsant response was chosen for 
the following anticonvulsant tests. All procedures were conducted following the care 
principles for the management of laboratory animals according to Resolution 008430 
of 1993, Title V, Ministry of Social Protection, Colombia. The Ethics Committee of 
the Faculty of Sciences at the National University of Colombia endorsed this study.
•	 Rota	 rod: It is a test to detect potentially neurotoxic agents [22]. Groups of 
seven animals were trained to maintain their balance on an axis of three cm in 
diameter powered by a small engine at 10 rpm. Mice were previously trained on 
the rota-rod for 3 min at a speed of 10 rpm. For testing, the animals were placed 
on the rota-rod one hour after the administration of pyrazole compounds (300 
mg/kg, p.o.), valproic acid (reference agent, 300 mg/kg, p.o.) or vehicle (con-
trol: hydroxypropylmethylcellulose -hpmc- 0.2%, by volume of 0.01 ml/g, p.o.) 
before wiring and MES text. A neurotoxic effect was assumed when the animals 
did not have demonstrated their ability to remain on the revolving rod for at 
least 1 minute.
•	 Grip	strength (wiring test): It is another test to detect potentially neurotoxic 
agents [23, 24]. Mice were previously exposed to a horizontal thin threat or 
metallic wire suspended about 30 cm into the air, which they immediately grasp 
with the forepaws. Mice were released to hang on with their forelimbs. Animals 
were previously trained to be able to catch the threat with the hind limbs and to 
climb up within 5 s. For testing, the animals were placed on the wire one hour 
after the administration of pyrazole compounds (300 mg/kg, p.o.), valproic acid 
(reference agent, 300 mg/kg, p.o.) or vehicle (hpmc 0.2%, 0.01 ml/g, p.o.). Ani-
mals which were not able to touch the threat with the hind limbs within 5 s or 
fall off from the threat were considered to be impaired. After this test mice were 
exposed to MES test.
•	 Maximal	electroshock	seizures (MES): It is a test to identify potentially effec-
tive agents in preventing tonic and clonic seizures. Groups of seven animals were 
dosed with all pyrazole compounds (300 mg/kg, p.o.), valproic acid (reference 
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agent, 300 mg/kg, p.o.) or vehicle (control: hpmc, 0,2%, p.o.) one hour prior 
to exposure to an electric shock of 50 mA, 60 Hz and 30 ms through corneal 
electrodes (E13-51, CI stimulator). A protective effect was assumed when the 
agent prevented the tonic extension of hind legs at an angle greater than 45° 
[25]. According the results of this test, MH4b1 was chosen to follow a dose 
response assay of 50, 150 and 300 mg/kg. p.o., against maximal electroshock sei-
zures (sodium phenytoin: second reference agent, 20 mg/kg, p.o.) and seizures 
induced by pentylenetetrazole (PTZ), picrotoxin (PIC), strychnine (STR) and 
6 Hz discharges.
•	 Seizures	 induced	 by	 pentylenetetrazole (PTZ): A test to detect potentially 
effective agents to prevent absence seizures. Groups of seven animals dosed one 
hour prior with MH4b1 (50, 150 and 300 mg/kg, p.o.), clonazepam (reference 
agent, 0.5 mg/kg, p.o.) or vehicle were administered PTZ (GABA-A antagonist, 
85 mg/kg, s.c.). An animal that did not show clonic seizures in its head, back 
or limbs for more than five seconds over 30 minutes of observation after PTZ 
administration was considered to be protected [22].
•	 Seizures	induced	by	picrotoxin (PIC): A test used to characterize the anticon-
vulsant pharmacology of test substances. Groups of seven animals dosed one 
hour prior with MH4b1 (50, 150 and 300 mg/kg, p.o.), diazepam (reference 
agent, 10 mg/kg, p.o.) or vehicle were administered PIC (GABA-A receptor 
antagonist, 3.5 mg/kg, s.c.). An animal that did not show clonic seizures in its 
head, back or limbs for more than five seconds over 30 minutes of observation 
after PIC administration was considered to be protected [26].
•		 Seizures	 induced	by	strychnine (STR): Another test used to characterize the 
anticonvulsant pharmacology of test substances. Groups of seven animals dosed 
one hour prior with MH4b1 (50, 150 and 300 mg/kg, p.o.), phenobarbital (ref-
erence agent, 20 mg/kg, p.o.) or vehicle were administered STR (glycine recep-
tor antagonist, 2.0 mg/kg, s.c.). An animal that did not show tonic seizures in its 
head, back or limbs for more than five seconds over 30 minutes of observation 
after STR administration was considered to be protected [26].
•		 6	Hz	psychomotor	 seizure	model: It is a test to identify potentially effective 
agents for partial refractory epilepsy [27]. Groups of seven animals were dosed 
with MH4b1 (50, 150 and 300 mg/kg, p.o.), levetiracetam (reference agent, 35 
mg/kg, p.o.) or vehicle one hour prior to exposure to an electric shock of 50 mA, 
6 Hz and 3 s through corneal electrodes (E13-51, CI stimulator). A protective 
effect was assumed when the agent prevented forelimb clonus, twitching of the 
vibrissae, and Straub-tail [28].
30
H. Insuasty, É. Castro, J. Escobar, V.Murillo, J. Rodríguez, L. Cuca, M. Estrada, B. Insuasty, M. Guerrero
Drugs,	reagents	and	solutions	
The following drugs and reagents were used: hydroxypropylmethylcellulose (hpmc, 
Sigma-Aldrich), valproic acid (VPA, Abbot®), sodium phenytoin (PHE, Parke Davis®), 
clonazepam (CZP, Roche®), diazepam (DZP), pentylenetetrazole (PTZ), picrotoxin 
(PIC) and strychnine (STR) (Sigma®). The reference agents (VPA, PHE, CZP and 
DZP) were prepared in hpmc, 0.2%. The chemical convulsants (PTZ, PIC and STR) 
were prepared in saline solution 0.9%.
Experimental	design	and	data	analysis	
The experiments followed a randomized design with 7-8 replicates per treatment. 
Results are expressed as frequency of protection. The Fisher exact test was applied 
according to its dichotomous response. Data were analyzed with Excel and Graph Pad® 
packages. A p value of 0.05 was assumed to be statistically significant.
Results
•		 Rotarod	 and	 grip	 strength: The administration of pyrazolo[1,5-α]-1,3,5-
triazines: EAC1, EAC-31, EAC-33, MH4a, MH4b1 and MH4c had no gross 
effect on motor coordination according to results in the rotating shaft and wiring 
test. The animals remained on the revolving rod for at least 1 minute (6-7/8) and 
were able to touch the threat with the hind limbs within 5 s or fall off from the 
threat (7/8), in a similar way than the reference agent, valproic acid (7/8; 6/8) 
and control (vehicle, 8/8; 7/8) (p>0.05) (Figure 2).
•	 MES	seizures: No pyrazolo[1,5-a][1,3,5]triazines but MH4b1 showed protec-
tion against maximal electroshock seizures (0/7 versus 5/7) at 300 mg/kg p.o., 
of screening dose whereas the protection afforded by the reference agent valproic 
acid (300 mg/kg, p.o.) was completed (8/8, Figures 2). The control group hpmc 
(0.2%, 0.1 ml/10g) did not prevent any seizure. MH4b1 showed a dose-depen-
dent response in the 50, 150 and 300 mg/kg, p.o., range (3/7, 4/7, 5/7; p < 0.05). 
Sodium phenytoin (reference agent, 20 mg/kg, p.o.) also conferred protection 
against MES (Figure 3). 
•		 PTZ,	PIC,	STR	and	6	Hz	seizures: MH4b1 (50, 150, 300 mg/kg., p.o) did not 
show any protection against chemical seizures induced by PTZ, PIC and STR 
(0/7, 0/7, 0/7) at 300 mg/kg p.o., whereas the protection afforded by the refer-
ence agent CZP (0.5 mg/kg, p.o.) and diazepam (10 mg/kg, p.o.) was significant 
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Figure 2. Effect of pyrazolo[1,5-a][1,3,5]triazines (300 mg/kg p.o.) in rota rod, wiring and maximal 
electroshock seizures test in ICR albino male mice. Reference agent: Valproic acid (VPA, 300 mg/
kg, p.o.). *p < 0.05 against control, n: 7-8/per group.
(6/8, 5/7 respectively, p < 0.05, Figures 4-5). Phenobarbital (20 mg/kg, p.o.) did 
not protect against STR either (data no shown). The control group hpmc (0.2%, 
0.1 ml/10g) did not prevent any seizure. In 6 Hz seizure test, MH4b1 showed a 
significant effect at 300 mg/kg, p.o., dose (4/7; p < 0.05) (Figure 6).
Discussion
The results of this study show that among this kind of pyrazolo[1,5-a][1,3,5]triazines, 
only MH4b1: 2-ethylthio-7-methyl-4-(4-methylphenyl)pyrazolo[1,5-a][1,3,5]triaz-
ine exerts significant effects on the maximal electroshock seizures (MES) screening test 
in mice and 6 Hz psychomotor seizure model whereas it lacks activity against penty-
lenetetrazole (PTZ), picrotoxine (PIC) and strychnine (STR) seizure tests. Although 
the compounds EAC-21, EAC-31 y EAC-33 attained protection in one/two animals, 
these results were not significant.
32
H. Insuasty, É. Castro, J. Escobar, V.Murillo, J. Rodríguez, L. Cuca, M. Estrada, B. Insuasty, M. Guerrero
Figure 3. Effect of MH4b1 (50, 150, 300 mg/kg, p.o.) in MES test in albino mice. *p < 0.05 against 
control. Reference agent: sodium phenytoin (PHEN, 20 mg/kg, p.o.).
Figure 4. Effect of MH4b1 (50, 150, 300 mg/kg, p.o.) in PTZ test in albino mice. *p < 0.05 against 
control. Reference agent: clonazepam (CZP, 0.5 mg/kg, p.o.).
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Figure 5. Effect of MH4b1 (50, 150, 300 mg/kg, p.o.) in PIC test in albino mice. *p < 0.05 against 
control. Reference agent: diazepam (DZP, 10 mg/kg, p.o.).
Figure 6. Effect of MH4b1 (50, 150, 300 mg/kg, p.o.) in 6 Hz seizure test in albino mice. *p < 0.05 
against control. Reference agent: levetiracetam (LEV, 35 mg/kg, p.o.).
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At the same time, MH4b1 would be devoid of acute neurotoxic effects, according to 
the results in rotarod and grip strength tests. The corollary of these experiments sug-
gests that MH4b1 could have anticonvulsant activity against tonic clonic and refrac-
tory partial seizures, a supposition supported by the selective inhibitory effects on 
MES and 6 Hz tests. 
MES, PTZ, PIC and STC tests are among the screening models used to explore pos-
sible anticonvulsant effects of a new compound [26]. MES is a useful test to explore 
possible anticonvulsant activity against tonic clonic seizures, usually related to direct 
or indirect sodium channels inhibition, although another mechanisms could be impli-
cated [17]. PTZ test is useful to detect agents against myoclonic seizures and with 
a lesser degree of predictivity, against absence seizures ([17]. This kind of seizures is 
related to T-type Ca2+ channel activation and/or GABA-A inhibition. Clonic sei-
zures induced by PIC and tonic seizures induced by STR are related to inactivation of 
chloride ion channel of GABA-A and glycine receptor respectively [29, 30]. Therefore, 
according to the results of this work, the lack of response to MH4b1 administration in 
the PTZ, PIC and STC tests leads to the suggestion that the mechanism of action of 
this agent is not related to either interactions with T-type Ca2+ channel or GABA-A 
receptor nor glycine receptors whereas some kind of inhibition against sodium chan-
nels could be implicated.
In addition, 6 Hz tests are among the screening models used to explore possible anti-
convulsant effects against refractory partial epilepsy [27]. 20–40% of the patients with 
newly diagnosed epilepsy will become refractory to conventional antiepileptic drugs, 
so there is need to finding drugs effective for the treatment of this kind of epilepsy 
[31]. Most of conventional antiepileptic drugs (AEDs) are not effective in 6 Hz model. 
Only few agents like levetiracetam, valproate and novel AEDs such as brivaracetam 
and retigabine, allow complete protection against the 6-Hz seizures [27]. Interestingly, 
MH4b1 also gives protection against 6 Hz model, which increases the potential utility 
of this agent. Given that MH4b1 protects against MES and 6 Hz seizures, additional 
mechanisms to sodium channels inhibition could be considered, since sodium antago-
nism could be suffice to protect against MES but not against 6 Hz test. In fact, typical 
sodium antagonists, such as phenytoin and carbamazepine, display anticonvulsant pro-
file mainly directed to generalized tonic clonic seizures but not to refractory seizures.
The structure of MH4b1 seems to show that the substitution at position 4 of the aro-
matic ring could play a pivotal role in the anticonvulsant activity of the pyrazolo[1,5-a]
[1,3,5]triazine. The effect would be greater with an electron donor group.
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Conclusions
In conclusion, MH4b1 has in vivo profile in mice consistent with anticonvulsant-like 
effects against generalized tonic clonic seizures and refractory partial seizures. More 
research is needed in order to establish its mechanism of action, its structure activity 
relationship and its pharmacokinetic features that let to MH4b1 attain the central ner-
vous system in enough amount to exert anticonvulsant properties.
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